Viewing Study NCT04895358


Ignite Creation Date: 2025-12-25 @ 12:04 AM
Ignite Modification Date: 2025-12-25 @ 10:03 PM
Study NCT ID: NCT04895358
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-03-03
First Post: 2021-05-17
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module